The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis

키워드

참고문헌 (42)

1. Svensson HK, "A painful, never ending story: older women's experiences of living with an osteoporotic vertebral compression fracture", Osteoporos Int, 27, pp.1729~1736 (2016)
2. 박찬미, "Incidence and Mortality after Proximal Humerus Fractures Over 50 Years of Age in South Korea: National Claim Data from 2008 to 2012", 대한골대사학회지, 22(1), pp.17~21 (2015), 대한골대사학회[DOI]
3. 임군일, "Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review", 대한골대사학회지, 22(4), pp.183~189 (2015), 대한골대사학회
4. Choi NK, "Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study", J Bone Miner Res (2016)
5. Bilezikian JP, "Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis", Am J Med, 122, pp.S14~S21 (2009)
6. van de Glind EM, "Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate", Drugs Aging, 33, pp.347~353 (2016)
7. Chao M, "Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women", Pak J Med Sci, 29, pp.1381~1384 (2013)
8. Bai H, "Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women", J Int Med Res, 41, pp.697~704 (2013)
9. Ou YJ, "Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies", Pharmacoepidemiol Drug Saf, 25, pp.1107~1115 (2016)
10. Wang J, "Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials", Osteoporos Int, 27, pp.1683~1690 (2016)
11. Shamseer L, "Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation", BMJ, 349, pp.g7647~ (2015)
12. Shea BJ, "Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews", BMC Med Res Methodol, 7, pp.10~ (2007)
13. Wells G, "Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women", Cochrane Database Syst Rev, pp.Cd004523~ (2008)
14. Wells GA, "Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women", Cochrane Database Syst Rev, pp.Cd003376~ (2008)
15. Wells GA, "Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women", Cochrane Database Syst Rev, pp.Cd001155~ (2008)
16. Zhou J, "Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis: a systematic review with network meta-analyses", Rheumatol Ther, 3, pp.117~128 (2016)
17. Higgins JPT, "Cochrane handbook for systematic reviews of interventions version 5.0.0" (2008), The Cochrane Collaboration
18. Borenstein M, "Introduction to meta-analysis" (2009), John Wiley & Sons
19. Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group", Lancet, 348, pp.1535~1541 (1996)
20. Boonen S, "Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study", J Bone Miner Res, 24, pp.719~725 (2009)
21. Boonen S, "Fracture risk and zoledronic acid therapy in men with osteoporosis", N Engl J Med, 367, pp.1714~1723 (2012)
22. Chesnut CH, 3rd, "Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis", J Bone Miner Res, 19, pp.1241~1249 (2004)
23. Clemmesen B, "A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis", Osteoporos Int, 7, pp.488~495 (1997)
24. Cummings SR, "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial", JAMA, 280, pp.2077~2082 (1998)
25. Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group", JAMA, 282, pp.1344~1352 (1999)
26. Herd RJ, "The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study", Am J Med, 103, pp.92~99 (1997)
27. Hosking D, "Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group", N Engl J Med, 338, pp.485~492 (1998)
28. Liberman UA, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group", N Engl J Med, 333, pp.1437~1443 (1995)
29. Lyles KW, "Zoledronic acid and clinical fractures and mortality after hip fracture", N Engl J Med, 357, pp.1799~1809 (2007)
30. Matsumoto T, "Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study", Osteoporos Int, 20, pp.1429~1437 (2009)
31. McCloskey E, "Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study", J Bone Miner Res, 19, pp.728~736 (2004)
32. McClung MR, "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group", N Engl J Med, 344, pp.333~340 (2001)
33. Meunier PJ, "Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)", J Clin Endocrinol Metab, 82, pp.2784~2791 (1997)
34. Orwoll E, "Alendronate for the treatment of osteoporosis in men", N Engl J Med, 343, pp.604~610 (2000)
35. Pouilles JM, "Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy", Osteoporos Int, 7, pp.213~218 (1997)
36. Reginster J, "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group", Osteoporos Int, 11, pp.83~91 (2000)
37. Reid IR, "Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis", J Clin Endocrinol Metab, 79, pp.1595~1599 (1994)
38. Storm T, "Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis", N Engl J Med, 322, pp.1265~1271 (1990)
39. McCloskey EV, "Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study", J Bone Miner Res, 22, pp.135~141 (2007)
40. Johnell O, "An estimate of the worldwide prevalence, mortality and disability associated with hip fracture", Osteoporos Int, 15, pp.897~902 (2004)
41. Jansen JP, "The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis", Semin Arthritis Rheum, 40, pp.275~284 (2011)
42. 이유진, "Which Bisphosphonate? It’s the Compliance!: Decision Analysis", 대한골대사학회지, 23(2), pp.79~83 (2016), 대한골대사학회[DOI]

관련 논문AI추천